Has Walter Delong, APRN received payments from drug or device companies?

Yes. Drug and device makers reported $448 in general payments to Walter Delong, APRN across 17 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Walter Delong, APRN did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Walter Delong, APRN come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Walter Delong, APRN

Acute Care · Tulsa, OKNPI 1992173454

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Organogenesis Inc. at 27.7% of the total. That places this record below the midpoint for acute care clinicians in OK, where the typical reported total is $433.

$448in general payments, 2019–2025

Across 17 payments — averaging $26.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Organogenesis Inc.$124
OPKO Pharmaceuticals, LLC$60
AstraZeneca$43
Vifor Pharma, Inc.$38
Novo Nordisk$37
Smith+Nephew$30
plus $116 from 5 others

What the payments were for

Food & beverage$448100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Organogenesis Inc.	1	$124
OPKO Pharmaceuticals, LLC	4	$60
AstraZeneca	2	$43
Vifor Pharma, Inc.	2	$38
Novo Nordisk	2	$37
Smith+Nephew	1	$30
Daiichi Sankyo Inc.	1	$28
Calliditas Therapeutics US Inc.	1	$28
Otsuka America Pharmaceutical, Inc.	1	$21
Aurinia Pharma U.S., Inc.	1	$20
Solventum Corporation	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$448 in reported general payments places this provider in the 50th percentile of 266 acute care providers in Oklahoma.

See all acute care providers in Oklahoma →

Medicare billing

Part B allowed, 2024

$142,164

Medicare patients

101

Services billed

1,633

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other acute care in Tulsa

See the full list for Oklahoma →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →